Advertisement

Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim–Chester disease

  • Xin-xin Cao
  • Na Niu
  • Jian Sun
  • Hao Cai
  • Feng-dan Wang
  • Yi-ning Wang
  • Ming-hui Duan
  • Dao-bin Zhou
  • Jian LiEmail author
Open Access
Research
  • 248 Downloads
Part of the following topical collections:
  1. Haematology

Abstract

Background

Erdheim–Chester disease (ECD) is a rare multi-systemic form of histiocytosis. Treatment with BRAF inhibitors has markedly improved outcomes of ECD; however, this targeted therapy is expensive (estimated annual cost is $50,000). Since estimated annual cost of interferon-α (IFN-α) is only approximately $1600 in China, we retrospectively evaluated the long-term therapeutic efficacy of IFN-α and the value of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) as an assessment method among 32 ECD patients who received high dose IFN-α therapy at Peking Union Medical College Hospital.

Results

The median age at diagnosis was 48 years (range, 6–66 years). The median duration of treatment was 18.5 months (range, 1–51 months). The overall clinical response rates were 80.0%, including 33.3% complete response, 36.7% partial response and 10.0% stable disease. Thirty-one patients underwent a total of 81 scans by FDG-PET. Seventeen patients had serial FDG-PET results, nine patients had experienced a partial metabolic response at the last follow-up. The median reduction of ratios between the most active target lesion standardized uptake value (SUV) and liver SUV from baseline to last FDG-PET scan was 61.4% (range, 8.8–86.6%). Eight of thirteen patients who experienced continuous clinical improvement during follow-up had at least one target lesion SUV increased by FDG-PET which decreased in subsequent scans without changing treatment strategy. The estimated 3-year progression-free survival (PFS) and overall survival (OS) were 64.1 and 84.5%, respectively. Central nervous system (CNS) involvement was the only predictor for poor PFS and OS.

Conclusions

High-dose IFN-α treatment is a cost-effective option, especially for patients without CNS involvement. Single target lesion SUV elevation according to FDG-PET do not accurately demonstrate disease progression, but serial FDG-PET imaging effectively discriminate treatment response.

Keywords

Erdheim–Chester disease BRAFV600E mutation Interferon-α Positron-emission tomography 

Abbreviations

CNS

Central nervous system

CR

Complete response

CT

Computed tomography

ECD

Erdheim–Chester disease

FDG-PET

18F-fluorodeoxyglucose positron emission tomography

IFN-α

Interferon-α

IL

Interleukin

LCH

Langerhans cell histiocytosis

MRI

Magnetic resonance imaging

OS

Overall survival

PD

progressive disease

PFS

Progression-free survival

PR

Partial response

SD

Stable disease

SUV

Standardized uptake value

TNF

Tumor necrosis factor

Introduction

Erdheim–Chester disease (ECD) is a rare multi-systemic form of histiocytosis that is characterized by infiltration of lipid-laden foamy macrophages into different tissues. The clinical spectrum of ECD ranges from asymptomatic to life-threatening multi-organ involvement, as pathologic histiocytes can infiltrate virtually every organ and tissue [1, 2].

Recurrent somatic activating mutations of BRAFV600E are found in 57% of archived Langerhans cell histiocytosis (LCH) lesions [3] and in 50–70% of infiltrating histiocytes sampled from ECD lesions [2, 4]. The concomitant occurrence of LCH and ECD (mixed histiocytosis) is not fortuitous and may linked to BRAFV600E mutation [5]. Since 2015, the use of the BRAF inhibitor vemurafenib has changed the initial treatment approach in 50–70% of patients with ECD [6]. However, the optimum duration of treatment with vemurafenib remains unknown, and 75% of patients relapse after stopping this targeted therapy [7]. As a consequence, treatment might need to be continued until either disease progression or intolerable adverse effects develop [8]. In addition, the estimated annual wholesale cost of vemurafenib is approximately 50,000 dollars in China, which is far beyond what most patients in low-income countries can afford. In an effort to looking for a cost-effective treatment option, we retrospective review the outcomes of Interferon-α (IFN-α) therapy among ECD patients in our center.

Historically, IFN-α has been used with variable efficacy as a treatment for ECD [9, 10]. The estimated annual cost of IFN-α is approximately 1600 dollars in China, which makes IFN-α still the first treatment option for ECD patients in low-resource countries [11]. However, the long-term outcomes of IFN-α therapy are unclear. Moreover,treatment evaluation of ECD is difficult given the rarity of this condition and the fact that it can affect multiple organs. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) scan was reported to be a good indicator of disease activity [12]. FDG-PET has been used to evaluate the overall therapeutic response of vemurafenib [6]. However, the role of serial FDG-PET imaging on clinical decision making in ECD patients treated with IFN-α had never been investigated.

The aim of the current study was to describe the long-term treatment outcomes and efficacy of FDG-PET for evaluating therapeutic responses among a cohort of ECD patients who were treated with IFN-α at Peking Union Medical College Hospital.

Methods

Patients

A retrospective review was conducted among patients who were diagnosed with ECD and had received high-dose IFN-α therapy for at least 1 month at Peking Union Medical College Hospital between January 2010 and May 2018. Diagnosis of ECD was based on typical clinical presentation, radiologic presentation, and histologic findings that were reviewed independently by two pathologists. Mixed histiocytosis (ECD & LCH) was diagnosed as previously described [5]. Informed consent was obtained from all patients and the protocol was approved by Peking Union Medical College Hospital Ethics Committee. The present study was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments.

Clinical, laboratory, imaging, and genetic data

Clinical data were collected regarding age, sex, lesion location, physical examination, routine biologic analysis, treatment, and survival. Serum level of the cytokines interleukin (IL)-6, IL-8, IL-10, and tumor necrosis factor (TNF)-α were measured by the electrochemiluminescence immunoassay (SIEMENS Immulite 1000). Imaging data were collected from FDG-PET, thoracic and abdominal computed tomography (CT), and cardiac and cerebral magnetic resonance imaging (MRI). The presence of the BRAFV600E mutation was detected by pyrosequencing or immunohistochemistry as previously described [2].

Treatment

High-dose IFN-α therapy was defined as the subcutaneous administration of either 600 MIU or 900 MIU of IFN-α, three times per week. Patients continued to receive IFN-α until two independent hematologists confirmed disease progression, intolerable adverse effects developed or the patient wished to stop treatment.

Response criteria

All patients were followed up every 3–6 months. Clinical responses were categorized as follows: (1) complete response (CR): complete resolution of symptoms attributed to ECD; (2) partial response (PR): partial resolution of symptoms attributed to ECD; (3) stable disease (SD): no change in symptoms attributed to ECD; or (4) progressive disease (PD): worsening of symptoms attributed to ECD [13].

Activity of ECD was evaluated based on the clinical response and CT, MRI and FDG-PET imaging changes at various sites of ECD involvement. Organ involvement was assessed by FDG-PET. MRI was used to detect CNS and cardiac lesions. Enhanced CT was used to assess vascular involvement.

Disease progression was defined as 1) clinical PD or new organ involvement detected by CT, MRI or FDG-PET or 2) clinical SD together with a minimum 30% increase in standardized uptake value (SUV) of target lesions confirmed by two separate FDG-PET scans taken at least 3 months apart.

Target lesions were defined as the most active lesion measured by SUV on FDG-PET before treatment. A second active lesion that could be followed on successive FDG-PET examinations was also studied for each patient. We used the ratios between the first (max 1) and second (max 2) most active target lesion SUV and liver SUV (SUVmax1/SUVliver and SUVmax2/SUVliver) for follow-up, to eliminate heterogeneity.

Data analysis

The Fisher exact test was used to compare categorical variables, whereas the Mann–Whitney test was used to compare continuous variables between groups. Overall survival (OS) was defined as the time from diagnosis to the date of death or last follow-up. Progression-free survival (PFS) was calculated from the date of diagnosis until the date of disease progression, relapse, or death from any cause. Kaplan–Meier analysis was used to assess survival analysis, with the survival curves compared using the log-rank test. We performed all statistical analyses using SPSS version 21 software (IBM Corp., Armonk, NY, USA), and considered P-values of less than 0.05 to be statistically significant.

Results

Characteristics of the patients

A total of 32 patients (16 male and 16 female) met the inclusion criteria. Four of them were diagnosed with mixed ECD and LCH. The median age at diagnosis was 48 years (range, 6–66 years).

The demographic and clinical characteristics of the patients are presented in Table 1. The median number of organs involved was 4 (range 1–8). The main sites of involvement were the bones (93.8%), retroperitoneum (40.6%), lungs (37.5%), vasculature (37.5%), central nervous system (CNS, 34.4%), pericardium (28.1%), pleura (21.9%), skin (18.8%), pituitary (15.6%), heart (12.5%), retro-orbital involvement (12.5%), nerve root (9.4%), muscles (6.3%), thymus (6.3%), thyroid (3.1%) and breasts (3.1%).
Table 1

Demographic and clinical characteristics of the ECD patients according to their BRAF status

Characteristic

Total cohort (n = 32)

BRAFV600E mutation (n = 21)

BRAF WT (n = 9)

P value

Age at diagnosis, years (median, range)

48 (6–66)

52 (6–66)

37 (32–56)

NS

Number of involved organs (median, range)

4 (1–8)

5 (2–8)

2 (1–7)

NS

organs of involvement

 Bone

30 (93.8%)

20 (95.2%)

8 (88.9%)

NS

 Retroperitoneum

13 (40.6%)

10 (47.6%)

2 (22.2%)

0.193

 Lungs

12 (37.5%)

9 (42.9%)

2 (22.2%)

NS

 Vasculature

12 (37.5%)

10 (47.6%)

1 (11.1%)

0.057

 Central nervous system

11 (34.4%)

8 (38.1%)

3 (33.3%)

NS

 Pericardium

9 (28.1%)

8 (38.1%)

1 (11.1%)

0.139

 Pleura

7 (21.9%)

7 (33.3%)

0 (0.0%)

0.048

 Skin

6 (18.8%)

4 (19.0%)

2 (22.2%)

NS

 Pituitary

5 (15.6%)

4 (19.0%)

1 (11.1%)

NS

 Heart

4 (12.5%)

2 (9.5%)

1 (11.1%)

NS

 Exophthalmos

4 (12.5%)

3 (14.3%)

1 (11.1%)

NS

 Nerve roots

3 (9.4%)

1 (4.8%)

1 (11.1%)

NS

WT wild type, NS not statistically significant

Two patients did not have an adequate amount of tissue available for genomic testing. BRAFV600E mutations were detected among 18/25 patients (72.0%) using PCR. Immunohistochemical analysis revealed positive staining for BRAFV600E for 6/13 patients (46.2%). Finally, we confirmed that 21/30 patients (70.0%) had a BRAFV600E mutation. Clinical presentation according to BRAFV600E status is listed in Table 1. Patients with the BRAFV600E mutation had more pleura involvement than did BRAF WT patients (p = 0.048). The data hint at a trend of more vascular, pericardial and retroperitoneal involvement in the BRAFV600E mutation group, but these differences did not reach statistical significance.

At baseline, 14 patients (43.8%) had an elevated platelet count. Twenty-three patients (71.9%) had elevated serum high sensitive C-reactive protein (hsCRP) levels. The erythrocyte sedimentation rate (ESR) level was elevated among 20/26 (76.9%) patients. Fibrinogen levels were elevated among 22/26 (84.6%) patients. Elevated serum IL-6 levels were found among 18/23 (78.3%) patients (Table 2). Elevated serum IL-8 levels were found among 10/21 (47.6%) patients. Elevated serum TNF α levels were detected among 20/22 patients (90.9%). None of these 21 patients had elevated IL-10 levels.
Table 2

Level of serum cytokines IL-6, IL-8 and TNF-α at baseline

 

Median (pg/mL)

Range (pg/mL)

Normal range (pg/mL)

IL-6 level

15.7

3.1–95.8

<  5.9

IL-8 level

54

5–755

<  62

TNF-α level

17.1

6.6–208.0

<  8.1

Treatment and clinical response

A total of 26 (81.3%) patients received IFN-α as the first-line treatment. One (3.1%) patient with the BRAFV600E mutation received vemurafenib after 3 months of treatment with IFN-α. Three (9.4%) patients who had mixed ECD and LCH received 6 courses of methotrexate (1 g/m2 on day 1) and cytarabine (100 mg/m2/d for 5 days) and then received IFN-α (600 MIU 3 times/week) for maintenance. One (3.1%) patient who had CNS and bone lesions received four courses of cytarabine 500 mg/m2 every 12 h for 3 days and then received IFN-α (600 MIU 3 times/week) for maintenance. Two (6.2%) patients received glucocorticoids as first-line therapy and received IFN-α after disease progression.

The median duration of follow-up was 24 months (range, 1–51 months). The median duration of IFN-α therapy was 18.5 months (range, 1–51 months). One patient stopped IFN-α treatment after 8 months owing to the development of anorexia and asthenia. Clinical responses were available for 30 of the 32 patients because two patients had received IFN-α for less than 3 months. The clinical response rates were as follows: CR, 33.3% (n = 10); PR, 36.7% (n = 11); SD, 10.0% (n = 3); and PD, 20.0% (n = 6).

Laboratory evaluation during treatment

Eighteen of 32 patients had serial results of hsCRP, IL-6, IL-8 and TNFα levels. Changes in the laboratory measures during treatment are shown in Fig. 1. Two of 18 patients experienced disease progression (red line in Fig. 1). One had elevated hsCRP levels, 1/2 had elevated IL-6 levels, 1/2 had elevated IL-8 levels, and 2/2 had elevated TNFα levels. One male patient died as a result of disease progression (blue line in Fig. 1): his serum levels of IL-6, IL-8 and TNFα increased over the time course. As shown in Fig. 1 (gray line), 14 of 18 patients displayed continuous clinical improvement during the follow-up period (CR = 9; PR = 5). At least one of the laboratory measures had increased by greater than 30% among 12 of these 14 patients. Without changing treatment, the level of elevated laboratory measures decreased at the subsequent follow-up.
Fig. 1

Changes in laboratory measures during treatment. a. Serum high sensitive CRP (hsCRP) levels; b Serum cytokines interleukin-6 (IL-6) levels; c Serum interleukin-8 (IL-8) levels; D. Serum tumor necrosis factor-α (TNF-α) levels. In all panels, the red lines represent patients who experienced disease progression during treatment. The blue lines represent patients who died during treatment. The gray lines represent patients who experienced continuous clinical improvement

FDG-PET follow-up

In all, 31 patients underwent a total of 81 FDG-PET scans. For each patient, we chose the two most active lesions as targets lesions. At recruitment, 30 patients underwent FDG-PET scans before treatment. The most active target lesions at baseline were bone (35/60, 58.3%), followed by CNS (n = 9, 15.0%), pleura (n = 3, 5.0%), nerve root (n = 3, 5.0%), muscle (n = 3, 5.0%), skin (n = 2, 3.3%), and heart, retroperitoneal, pericardium, thymus and vasculature (n = 1 each, 1.7%). A total of 17 patients underwent at least one follow-up FDG-PET scan, median of 4 [2, 3, 4, 5, 6]. The SUVmax1/SUVliver changed during treatment (Fig. 2a). At the last follow-up, nine (52.9%) of these patients had experienced a partial metabolic response. The median reduction in SUVmax1/SUVliver from baseline to last FDG-PET scan was 61.4% (range, 8.8–86.6%). In all, 13/17 (76.5%) patients experienced continuous clinical improvement during follow-up. Eight of 13 (61.5%) patients recorded at least one SUVmax1/SUVliver increase during follow-up: the median increase in this ratio was 32.0% (range, 2.6–45.4%). Figure 2b showed serial FDG-PET of one of these patients. Since none of them had clinical symptoms worsen, these 8 patients continued to received IFN-α therapy, and the SUVmax1/SUVliver according to the subsequent FDG-PET scans decreased (Fig. 3).
Fig. 2

The baseline and follow-up FDG-PET scans showed changes in SUVmax1/SUVliver during treatment. a Serial FDG-PET scans of 17 patients. The red lines represent patients who experienced disease progression during treatment. The blue lines represent patients who died during treatment. The gray lines represent patients who experienced continuous clinical improvement. b Serial FDG-PET scans of one patient who experienced continuous clinical improvement. The most active target lesion of the patient at baseline was right ilium (arrow). Compared with baseline, SUV max1/SUVliver increased at 3 months and 12 months after treatment. Without changing treatment strategy, SUV max1/SUVliver decreased at 18 months and 24 months after treatment

Fig. 3

Efficacy of interferon-α treatment among a subgroup of patients with ECD (n = 17)

Survival

Of the 32 patients included in the present study, three (9.4%) patients died and 8 (25.0%) experienced disease progression during follow-up. The estimated 3-year PFS and OS were 64.1 and 84.5%, respectively (Fig. 4a). The survival analyses showed that a significantly higher PFS was attained in patients without CNS involvement compared to those with CNS involvement (not reached vs 24 m, p = 0.018) (Fig. 4b). As shown in Fig. 4c, patients without CNS involvement also had a significantly higher OS than those with CNS involvement (p = 0.023). BRAF status was not an independent prognostic factor for PFS or OS.
Fig. 4

Survival for the whole cohort (n = 32). a PFS and OS. b Comparison of PFS according to CNS involvement. c Comparison of OS according to CNS involvement

Discussion

ECD is a rare non-Langerhans cell histiocytosis. In this study, we identified a pleura phenotype closely linked to the BRAF status. We also found a trend of more vascular, pericardial and retroperitoneal involvement in the BRAFV600E mutation group, as previous reported [14]. This indicated BRAF mutation status may denotes differences in disease presentation for patients with ECD.

Despite significant advances in our understanding of ECD, a standard treatment strategy is missing. Vemurafenib use in patients with BRAFV600E mutation have increased antitumor efficacy [6]. Other targeted therapies including MEK inhibitor [7] and anti-IL-6 agent tocilizumab [15] seem promising, but with limited experience. Anakinra may be used in combination with kinase inhibitors and is effective in some cases characterized by difficult involvement [16, 17, 18]. IFN-α has been used with variable efficacy as a treatment for ECD and long-term outcomes of IFN-α therapy are unclear. Our study is one of the largest cohorts to date evaluating the role of high-dose IFN-α therapy as a treatment for ECD. We demonstrate that IFN-α has favorable clinical efficacy among patients with ECD, even for the most severe cases with multiple organ involvement. The overall clinical response rate was 80.0%, with an estimated 3-year PFS and OS of 64.1% and 84.5%, respectively. These outcomes are much better than those of other non-targeted therapies for ECD (overall clinical response rate of methotrexate [13], cladribine [19] and anakinra [20] were 23%, 52% and 50% separately). And only one patient stopped IFN-α treatment due to intolerable adverse effects. Together with the annual cost of IFN-α is only approximately 1600 dollars, IFN-α should still be the first treatment option for ECD patients in low-income countries.

In the present retrospective study, we found that FDG-PET was able to globally depict both the extent and the activity of the ECD lesions. The sensitivity varied greatly among the different sites of involvement. We found FDG-PET scanning was very helpful in assessing bone and CNS involvement in ECD. The sensitivity for detecting cardiovascular involvement was low when compared with that of MRI and CT scans. In this study, the vasculature, pericardium and heart involvement is approximately 40%, 30% and more than 10% separately detected by MRI or CT scans. However, the 60 most active lesions detected by FDG-PET only included one cardiac lesion, one pericardium lesion and one vascular lesion.

Although treatment with vemurafenib can promote a significant and fast FDG-PET response [6, 8], ECD remains a slowly evolving histiocytosis. Consequently, use of non-targeted therapies, such as IFN-α, usually leads to partial remission rather than complete recovery. The mechanism of IFN-α therapy is thought to induce immune-mediated histiocyte killing and the terminal differentiation of immature histiocytes, which is like tumor immunotherapy and quite different from that of cytotoxic chemotherapy or targeted therapy. The best documentation of the mechanism of action of tumor immunotherapy has been achieved by analyzing serial biopsies of regressing metastases after treatment with anti-CTLA4 antibodies among melanoma patients; this demonstrated that some patients treated with anti-CTLA4 antibodies experienced increased objective tumor burden and/or new lesions before a response was obtained [21, 22]. Therefore, there is a different set of response assessment criteria for tumor immunotherapy in solid tumors. However, it is unknown whether the same situation applies to ECD patients treated with IFN-α. We found that eight of 13 patients who experienced continuous clinical improvement had at least one target lesion SUV increased during follow-up. This elevation could be greater than 40%. While these patients achieved durable clinical improvement and lesion SUV of their subsequent FDG-PET decreased without further changing treatment strategy, calling into question the value of single target lesion SUV elevation according to FDG-PET to demonstrating disease progression. Consequently, new response assessment criteria might be required for IFN-α or other immunotherapeutic approaches for ECD.

Patients with ECD have been reported to have elevated levels of IFN-α, IL-12, chemokine ligand 18 (CCL18) and monocyte chemotactic protein-1 but decreased levels of IL-4 and IL-7; however, a previous study failed to demonstrate that the cytokine levels were related to disease activity [23, 24]. To our knowledge, this study is the largest series reviewing series change of cytokine levels during the same treatment. We measured the levels of hsCRP, IL-6, IL-8 and TNFα every 3–6 months among 18 patients and demonstrated that the levels of these molecules decreased after treatment but increased at disease progression. However, like the value of single target lesion SUV elevation according to FDG-PET, one single elevation of cytokine levels is not enough to demonstrating disease progression.

ECD is a heterogeneous disease with a variable prognosis. Previous studies have reported that CNS involvement and IFN-α treatment are independent prognostic factors [10, 25]. In this study, we demonstrated that CNS involvement was associated with poor survival among IFN-α treated patients. BRAF status was not an independent prognostic factor. This finding indicates that ECD patients with CNS involvement should seek new treatment strategies, such as targeted therapy.

The main limitation of our study is that it is a single-institution retrospective study, which might limit the generalizability of our results. However, all the records were reviewed independently by two hematologists to minimize bias or errors in data collection.

Conclusion

In conclusion, high-dose IFN-α is a cost-effective treatment option, especially for patients without CNS involvement. We believe that single target lesion SUV elevation according to FDG-PET do not accurately demonstrate disease progression, but serial FDG-PET imaging effectively discriminate treatment response.

Notes

Acknowledgments

The authors thank the patients and their families.

Funding

Institutional research funding was provided by the CAMS Innovation Fund for Medical Sciences (Grant No. 2016-12 M-1-002), the National Key Research and Development Program of China (Grant No. 2016YFC0901503) and the Young Scientific Research Fund of PUMC (Grant No. 2017320004).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

Contribution:XC, DZ and JL contributed to the conception and design of the study; XC, MD and JL contributed to data collection; XC wrote the paper; NN assessed all PET/CT evaluation; FW assessed all CT evaluation; YW assessed all MRI evaluation; JS and HC performed BRAF mutation examination; JS and Ding-rong Zhong reviewed histologic findings independently and all authors revised the paper and approved the submitted version.

Ethics approval and consent to participate

Informed consent was obtained from all patients and the protocol was approved by Peking Union Medical College Hospital Ethics Committee. The committee’s reference number is S-K584.

Consent for publication

NA

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Cavalli G, Guglielmi B, Berti A, et al. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis. 2013;72(10):1691–5.CrossRefGoogle Scholar
  2. 2.
    Cao XX, Sun J, Li J, et al. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. Ann Hematol. 2016;95(5):745–50.CrossRefGoogle Scholar
  3. 3.
    Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919–23.CrossRefGoogle Scholar
  4. 4.
    Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700–3.CrossRefGoogle Scholar
  5. 5.
    Hervier B, Haroche J, Arnaud L, et al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood. 2014;124(7):1119–26.CrossRefGoogle Scholar
  6. 6.
    Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with Vemurafenib in patients with BRAFV600E-mutated Erdheim-Chester disease. J Clin Oncol. 2015;33(5):411–8.CrossRefGoogle Scholar
  7. 7.
    Cohen Aubart F, Emile JF, Carrat F, et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood. 2017;130(11):1377–80.CrossRefGoogle Scholar
  8. 8.
    Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell Histiocytosis: analysis of data from the histology-independent, phase 2. Open-label VE-BASKET Study JAMA Oncol. 2018;4(3):384–8.CrossRefGoogle Scholar
  9. 9.
    Braiteh F, Boxrud C, Esmaeli B, et al. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005;106(9):2992–4.CrossRefGoogle Scholar
  10. 10.
    Arnaud L, Hervier B, Neel A, et al. CNS involvement and treatment with interferon-alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778–82.CrossRefGoogle Scholar
  11. 11.
    Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483–92.CrossRefGoogle Scholar
  12. 12.
    Arnaud L, Malek Z, Archambaud F, et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum. 2009;60(10):3128–38.CrossRefGoogle Scholar
  13. 13.
    Goyal G, Shah MV, Call TG, et al. Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease. Blood Cancer J. 2017;7(12):647.CrossRefGoogle Scholar
  14. 14.
    Cohen-Aubart F, Emile JF, Carrat F, et al. Phenotypes and survival in Erdheim-Chester disease: Results from a 165-patient cohort. Am J Hematol. 2018;93(5):vE114–7.CrossRefGoogle Scholar
  15. 15.
    Berti A, Cavalli G, Guglielmi B, et al. Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology. 2017;6(6):e1318237.CrossRefGoogle Scholar
  16. 16.
    Tomelleri A, Cavalli G, De Luca G, et al. Treating heart inflammation with Interleukin-1 blockade in a case of Erdheim-Chester disease. Front Immunol. 2018;9:1233.CrossRefGoogle Scholar
  17. 17.
    Aouba A, Georgin-Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116(20):4070–6.CrossRefGoogle Scholar
  18. 18.
    Franconieri F, Martin-Silva N, de Boysson H, et al. Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: towards the paradigm of combined targeting and immune therapies. Acta Oncol. 2016;55(7):930–2.CrossRefGoogle Scholar
  19. 19.
    Goyal G, Shah MV, Call TG, et al. Clinical and radiologic responses to Cladribine for the treatment of Erdheim-Chester disease. JAMA Oncol. 2017;3(9):1253–6.CrossRefGoogle Scholar
  20. 20.
    Goyal G, Shah MV, Call TG, et al. Efficacy of biological agents in the treatment of Erdheim-Chester disease. Br J Haematol. 2017.  https://doi.org/10.1111/bjh.14997.
  21. 21.
    Ribas A, Comin-Anduix B, Economou JS, et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res. 2009;15(1):390–9.CrossRefGoogle Scholar
  22. 22.
    Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–20.CrossRefGoogle Scholar
  23. 23.
    Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood. 2011;117(10):2783–90.CrossRefGoogle Scholar
  24. 24.
    Pacini G, Cavalli G, Tomelleri A, et al. The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. Oncoimmunology. 2018;7(7):e1440929.CrossRefGoogle Scholar
  25. 25.
    Toya T, Ogura M, Toyama K, et al. Prognostic factors of Erdheim-Chester Disease: A nationwide survey in Japan. Haematologica. 2018.  https://doi.org/10.3324/haematol.2018.190728.

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  • Xin-xin Cao
    • 1
  • Na Niu
    • 2
  • Jian Sun
    • 3
  • Hao Cai
    • 1
  • Feng-dan Wang
    • 4
  • Yi-ning Wang
    • 4
  • Ming-hui Duan
    • 1
  • Dao-bin Zhou
    • 1
  • Jian Li
    • 1
    Email author
  1. 1.Department of HematologyPeking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijingChina
  2. 2.Department of Nuclear MedicinePeking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijingChina
  3. 3.Department of PathologyPeking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijingChina
  4. 4.Department of RadiologyPeking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical CollegeBeijingChina

Personalised recommendations